Effect of Milk Thistle on relieving infertility in women with polycystic ovaries

Evaluation the effect of silymarin on serum oxidative stress markers and in vitro fertilization outcome in patients with polycystic ovarian syndrome

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015041321743N1

Enrollment

Registered

2015-06-16

Start date

2014-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovarian syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention 1. Silymarin tablet, 70 mg, three times a day, orally, made in Gol Daroo company, Iran. Intervention 2: Intervention 2. Placebo tablet, three times a day, orally.

Treatment - Drugs

Placebo

Intervention 1. Silymarin tablet, 70 mg, three times a day, orally, made in Gol Daroo company, Iran.

Intervention 2. Placebo tablet, three times a day, orally.

Eligibility

Sex/Gender

Female

Age

20 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patient satisfaction; Age between 20-35 years old; Patients with PCOS. Exclusion criteria: Patients with diabetes mellitus or hypertension; Cigarette smoking; Using antioxidant drugs currently or in the past 3 months; Multifactorial infertility.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Paraoxonase enzyme activity. Timepoint: Before using silymarin and after completing usage. Method of measurement: Elisa kit.;Malondialdehyde concentration. Timepoint: Before using silymarin and after completing usage. Method of measurement: Elisa kit.;C-reactive protein level. Timepoint: Before using silymarin and after completing usage. Method of measurement: Elisa kit.;Number of follicles. Timepoint: After completing silymarin usage. Method of measurement: ultrasonography.;Endometrial thickness. Timepoint: After completing silymarin usage. Method of measurement: ultrasonography.	—

Measure

Time frame

Paraoxonase enzyme activity. Timepoint: Before using silymarin and after completing usage. Method of measurement: Elisa kit.;Malondialdehyde concentration. Timepoint: Before using silymarin and after completing usage. Method of measurement: Elisa kit.;C-reactive protein level. Timepoint: Before using silymarin and after completing usage. Method of measurement: Elisa kit.;Number of follicles. Timepoint: After completing silymarin usage. Method of measurement: ultrasonography.;Endometrial thickness. Timepoint: After completing silymarin usage. Method of measurement: ultrasonography.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Nazila Najdi

Tehran University of Medical Sciences

najdinnazila@yahoo.com+98 21 8889 7761

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026